Compare Walt Disney Co (DIS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Walt Disney Co vs Novo Nordisk A/S — how do they compare? Walt Disney Co trades at $108.05 (market cap $184.79B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Walt Disney Co and Novo Nordisk A/S are close in size by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Walt Disney Co for 199 Days and Novo Nordisk A/S for 116 Days on average.
| DIS | NVO | |
|---|---|---|
Market Cap | $184.79B | $165.31B |
Volume | 13,033,550 | 11,432,838 |
Sector | Media | Health |
52-Week High | $116.65 | $63.98 |
52-Week Low | $92.40 | $35.29 |
Typical Hold Time | 199 Days | 116 Days |
Enterprise Value | $225.65B | $179.56B |
Dividend Yield | 1.4% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $107.08, up 2.21% today, with a bullish technical signal from moving averages and consistent earnings beats in recent quarters. Revenue grew to $94.43B in 2025, with net income surging to $12.40B, though free cash flow faces pressure from increased investments. The stock remains below the analyst consensus price target of $125.67, indicating potential upside.
The outlook is positive with strong fundamentals and analyst support, but risks include streaming competition and high capital expenditures. Investment opportunity lies in execution of the $60B parks pipeline and streaming margin expansion, balanced against macroeconomic sensitivity and execution risks.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Walt Disney Co
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
